{"filing":{"accession_number":"0001193125-26-377059","cik":"0000921299","ticker":"KYNB","company_name":"KYNTRA BIO, INC.","form":"8-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"kynb-20260831.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526377059/kynb-20260831.htm"},"events":[{"id":30692,"run_id":28138,"accession_number":"0001193125-26-377059","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"summary":"Kyntra Bio amended and restated its Revenue Interest Financing Agreement with NQ Project Phoebus, L.P., reducing maximum aggregate payments from $125 million to $65 million through a $42.6 million accelerated upfront payment. Combined with the FibroGen Europe bankruptcy settlement, the company reduced future liabilities by approximately $80 million, materially strengthening its balance sheet and extending cash runway into Q4 2027.","company_name":"KYNTRA BIO, INC.","ticker":"KYNB","filing_date":"2026-08-31","form":"8-K","submitted_at":null,"items":[{"id":33363,"accession_number":"0001193125-26-377059","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.35,"reasoning":"This disclosure centers on amendment of an existing Revenue Interest Financing Agreement (RIFA), reducing maximum aggregate payments from $125M to $65M and requiring a $42.6M accelerated upfront payment. While the transaction materially restructures Kyntra Bio's financial obligations and improves its balance sheet, the core event is a modification of an existing direct financial obligation rather than creation of new debt. The RIFA is a royalty-based financing instrument (a form of structured debt), and the amendment fundamentally alters its terms. However, this could also be classified as `financial_other` (asset sale/restructuring) or `ma_activity` if viewed as a material transaction. The amendment reduces rather than increases obligations, making `debt_issuance` imperfect, but it is the closest fit among the taxonomy options for a material modification of a direct financial obligation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T21:19:45.262420+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33364,"accession_number":"0001193125-26-377059","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"The Item 2.03 disclosure centers on an amendment and restatement (A\u0026R) of an existing royalty financing agreement that materially restructures the Company's payment obligations. While the amendment reduces future liabilities by $60 million and involves an accelerated $42.6 million upfront payment, the core event is a modification of an existing direct financial obligation rather than creation of a new one. The disclosure also references the FibroGen Europe bankruptcy settlement, which reduced liabilities by approximately $19.1 million. Taken together, these actions reduced future liabilities by approximately $80 million, strengthening the Company's balance sheet and extending cash runway into Q4 2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T21:19:45.262420+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33365,"accession_number":"0001193125-26-377059","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Kyntra Bio announced an amendment to its royalty financing agreement with NQ Project Phoebus, L.P., reducing maximum aggregate payments from $125 million to $65 million through a $42.6 million accelerated upfront payment. This materially improves the company's balance sheet and liquidity position (pro forma cash of $53.1 million with runway into Q4 2027), reducing future liabilities by approximately $80 million when combined with the FibroGen Europe bankruptcy settlement. While this is a favorable financial restructuring rather than a debt issuance or covenant breach, it represents a material modification of a direct financial obligation that would affect a reasonable investor's assessment of the company's financial position and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T21:19:45.262420+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33363,"accession_number":"0001193125-26-377059","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.35,"reasoning":"This disclosure centers on amendment of an existing Revenue Interest Financing Agreement (RIFA), reducing maximum aggregate payments from $125M to $65M and requiring a $42.6M accelerated upfront payment. While the transaction materially restructures Kyntra Bio's financial obligations and improves its balance sheet, the core event is a modification of an existing direct financial obligation rather than creation of new debt. The RIFA is a royalty-based financing instrument (a form of structured debt), and the amendment fundamentally alters its terms. However, this could also be classified as `financial_other` (asset sale/restructuring) or `ma_activity` if viewed as a material transaction. The amendment reduces rather than increases obligations, making `debt_issuance` imperfect, but it is the closest fit among the taxonomy options for a material modification of a direct financial obligation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T21:19:45.262420+00:00","company_name":"KYNTRA BIO, INC.","ticker":"KYNB","filing_date":"2026-08-31"},{"id":33364,"accession_number":"0001193125-26-377059","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"The Item 2.03 disclosure centers on an amendment and restatement (A\u0026R) of an existing royalty financing agreement that materially restructures the Company's payment obligations. While the amendment reduces future liabilities by $60 million and involves an accelerated $42.6 million upfront payment, the core event is a modification of an existing direct financial obligation rather than creation of a new one. The disclosure also references the FibroGen Europe bankruptcy settlement, which reduced liabilities by approximately $19.1 million. Taken together, these actions reduced future liabilities by approximately $80 million, strengthening the Company's balance sheet and extending cash runway into Q4 2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T21:19:45.262420+00:00","company_name":"KYNTRA BIO, INC.","ticker":"KYNB","filing_date":"2026-08-31"},{"id":33365,"accession_number":"0001193125-26-377059","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Kyntra Bio announced an amendment to its royalty financing agreement with NQ Project Phoebus, L.P., reducing maximum aggregate payments from $125 million to $65 million through a $42.6 million accelerated upfront payment. This materially improves the company's balance sheet and liquidity position (pro forma cash of $53.1 million with runway into Q4 2027), reducing future liabilities by approximately $80 million when combined with the FibroGen Europe bankruptcy settlement. While this is a favorable financial restructuring rather than a debt issuance or covenant breach, it represents a material modification of a direct financial obligation that would affect a reasonable investor's assessment of the company's financial position and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T21:19:45.262420+00:00","company_name":"KYNTRA BIO, INC.","ticker":"KYNB","filing_date":"2026-08-31"}]}